Home / Market Reports / Medical Care / Global CHO Cell Line Construction Service Market Growth (Status and Outlook) 2024-2030

Global CHO Cell Line Construction Service Market Growth (Status and Outlook) 2024-2030

Global CHO Cell Line Construction Service Market Growth (Status and Outlook) 2024-2030

Product Code:1238081

Published Date: Nov 12,2024

Pages: 143

Region: Global

Category: Medical Care

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US 

The global CHO Cell Line Construction Service market size is projected to grow from US$ 1183 million in 2024 to US$ 2287 million in 2030; it is expected to grow at a CAGR of 11.6% from 2024 to 2030.

Chinese hamster ovary (CHO) cells are the primary mammalian cell lines utilized to produce monoclonal antibodies (mAbs). Cell Line Construction is the engineering of a cell line, often mammalian, to produce a therapeutic biomolecule or biologic. It allows scientists to tailor cultures depending on the applications and desired properties of the targeted product. Creating a robust, stable cell line that can yield sufficient material for testing, optimization, and manufacturing at commercial scales is a crucial step in bioprocess development.

United States market for CHO Cell Line Construction Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for CHO Cell Line Construction Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for CHO Cell Line Construction Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key CHO Cell Line Construction Service players cover Lonza, Thermo Fisher Scientific, Sartorius, Boehringer Ingelheim BioXcellence, WuXi Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

LPI (LP Information)' newest research report, the “CHO Cell Line Construction Service Industry Forecast” looks at past sales and reviews total world CHO Cell Line Construction Service sales in 2023, providing a comprehensive analysis by region and market sector of projected CHO Cell Line Construction Service sales for 2024 through 2030. With CHO Cell Line Construction Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CHO Cell Line Construction Service industry.

This Insight Report provides a comprehensive analysis of the global CHO Cell Line Construction Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CHO Cell Line Construction Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CHO Cell Line Construction Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CHO Cell Line Construction Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CHO Cell Line Construction Service.

This report presents a comprehensive overview, market shares, and growth opportunities of CHO Cell Line Construction Service market by product type, application, key players and key regions and countries.

Segmentation by Type:
    Knockout CHO Cell Lines
    Overexpression CHO Cell Lines
    Inducible Expression CHO Cell Lines
    Others

Segmentation by Application:
    Pharmaceuticals
    Bioengineering

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

Segmentation by Type:
    Knockout CHO Cell Lines
    Overexpression CHO Cell Lines
    Inducible Expression CHO Cell Lines
    Others

Segmentation by Application:
    Pharmaceuticals
    Bioengineering

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    Lonza
    Thermo Fisher Scientific
    Sartorius
    Boehringer Ingelheim BioXcellence
    WuXi Biologics
    Merck
    Catalent
    Samsung Biologics
    FUJIFILM Diosynth Biotechnologies
    Beckman Coulter
    Rentschler Biopharma
    ProBioGen
    AGC Biologics
    Guangzhou Cantonbio
    Charles River Laboratories
    Mycenax Biotech
    Shanghai Ruizhi Chemical Research
    Shanghai OPM Biosciences
    Beijing Joinn Biologics
    Chime Biologics
    Great Bay Bio